The race is continually heating up in the psychedelics space.
An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment.
The race has heated to such a degree that certain compounds, like psilocybin, have patent trackers to keep abreast of the market.
While exciting, the development of the space creates a discussion around psychedelic patent ethics.
In early 2021,
COMPASS Pathways PLC (NASDAQ:CMPS) made headlines for its patent applications. Unlike previously granted patents for formulations, Compass applied for patents on commonplace psychedelic experiences, including holding hands and comfortable furniture.